Eosinophil-associated diseases (EADs) are rare, heterogeneous disorders characterized by the presence of eosinophils in tissues and/or peripheral blood resulting in immunopathology. The heterogeneity of tissue involvement, lack of sufficient animal models, technical challenges in working with eosinophils, and lack of standardized histopathologic approaches have hampered progress in basic research. Additionally, clinical trials and drug development for rare EADs are limited by the lack of primary and surrogate endpoints, biomarkers, and validated patientreported outcomes. Researchers with expertise in eosinophil biology and eosinophil-related diseases reviewed the state of current eosinophil research, resources, progress, and unmet needs in the field since the 2012 meeting of the NIH Taskforce on the Research of Eosinophil-Associated
INTRODUCTION
In June 2012, a meeting of the National Institute of Health (NIH)
Taskforce on the Research of Eosinophil-Associated Diseases (TREAD) was convened with the aim of defining, clarifying, and prioritizing the unmet research and supportive needs of EADs, defined as rare conditions presenting with eosinophils in the peripheral blood and/or tissues with associated pathology. Although the number of citations with "eosinophil" in the subject or as a keyword has increased in the past 5 years (Fig. 1 ) and the clinical development and approval of therapeutic agents targeting eosinophils in more common eosinophil-related diseases, such as asthma, has brought new focus to the eosinophil, unmet needs remain in research of basic eosinophil biology and rare EADs. The Taskforce consisted of nationally and internationally recognized, basic, and clinical eosinophil researchers and patient advocacy groups (PAGs). The following 7 common unmet needs across the spectrum of EADs were identified: (1) creation of diagnostic codes to identify and define patient subsets; (2) in depth analysis of biological samples (to help standardize markers of eosinophilic tissue involvement and better understand disease pathogenesis); (3) development and validation of reliable testing for diagnosis and assessment of exacerbation of eosinophilic disease; (4) mechanistic understanding of the role of eosinophils in various EADs; (5) establishment of patient registries; (6) improved guidance and success of relevant clinical trials in rare disease patient populations; and (7) expansion of the number of useful therapeutics for treating EADs. 1 In response to this publication, the National Institute of Allergy and Infectious Diseases (NIAID) issued two funding announcements, which were co-sponsored by the National Heart Lung and Blood Institute, the National Institute of Arthritis and Musculoskeletal and Skin Diseases, and the National Institute of Diabetes and Digestive and Kidney Diseases. These announcements covered both exploratory (R21) and more established (R01) investigator-initiated basic and clinical/translational projects.
In 2017, an updated taskforce, "RE-TREAD", was organized during a meeting of the International Eosinophil Society to bring together a multidisciplinary group of clinicians and scientists with expertise in rare eosinophil-related disorders to discuss issues related to patient care and clinical trial design. A second meeting goal was to continue to foster collaborative relationships between multidisciplinary clinical and basic science researchers with the aim of improving diagnosis and treatment of EADs. This publication summarizes the conclusions of RE-TREAD and the state of eosinophil research in 2017. It also creates a road map for clinicians, PAGs, and other entities concerned with the health and treatment of patients with rare EADs.
METHODS
RE-TREAD was convened during the biennial meeting of the International Eosinophil Society in Göthenburg, Sweden in July 2017. 
RESULTS
In contrast to TREAD, which took an organ and disease-specific approach to define unmet needs in individual EADs, RE-TREAD focused on the following 3 main areas important to EADs as a whole:
(1) The role of eosinophils and eosinophil activation in the pathogenesis of EADs, (2) clinical and translational studies in EADs, and (3) development and standardization of novel techniques for the study of eosinophils and eosinophil-mediated pathogenesis.
The role of eosinophils in the pathogenesis of EADs
Despite the presence of eosinophils and evidence of eosinophil activation in the blood and tissues of patients with EADs, the precise role of eosinophils in disease pathogenesis remains unclear. The reasons for this are multifactorial and include the heterogeneity and complexity of these disorders, the lack of standardized methods to evaluate and target eosinophil-associated pathology, limitations in the recapitulation of human EADs in animal models, and gaps in our understanding of the basic biology of human eosinophils. Recent progress in these areas in the context of novel therapeutics targeting eosinophils, as well as recommendations for future research, are summarized in the next section.
Eosinophil histopathology
Standardization of methods for evaluation of eosinophil involvement in tissue pathology was identified by TREAD as an unmet need common to all EADs. Specific suggestions for eosinophilic esophagitis (EoE) Gastrointestinal Researchers (CEGIR (Table 1) ). It is anticipated that data generated from this consortium will help standardize methods to evaluate gastrointestinal biopsies across multiple centers and identify the relationship, if any, between eosinophilic gastrointestinal disorders (EGID) and other inflammatory bowel diseases.
TREAD also recommended the standardization and validation of methods to evaluate tissues to improve the differential diagnosis and treatment for organ-restricted EAD. Some progress has been made.
For example, using stains to identify Th1 (T-bet and CD4) or Th2
(GATA and CD4), a significantly lower Th1/Th2 cell ratio was identified in morphea compared to eosinophilic fasciitis, facilitating the distinction between these two disorders that share multiple histopathologic features (dermal inflammation including eosinophil infiltration and fibrosis extending into fascia). 6 Similarly, in the esophagus, Tbet (Th1) and GATA-3 (Th2) expression may help distinguish between EoE and gastroesophageal reflux disease (GERD 
Animal models of eosinophilic disease
At the time of TREAD, experts felt that existing murine models did not accurately recapitulate EADs, although they were felt to be important in understanding the basic biologic functions of eosinophils. TREAD recommended utilization of "humanized" murine models to better model human disease but recognized that species differences in sol- Because murine models can be manipulated in ways that are not currently possible in humans, they are critical to studies of eosinophil function. 11 Murine models have provided significant insight into allergic inflammation, 12 In a mouse model of severe asthma, EPX, but not eosinophil granule major basic protein-1 (eMBP-1) induced goblet cell metaplasia, 37 suggesting that the pattern of eosinophil granule protein release may be an important driver of a particular disease pathology. As such, granule specific assays, such as the EPX ELISA or EPX immunohistochemistry (Table 1, Supplementary Table S1 ), will help clarify these relationships and are likely to play a significant role in future assessments of eosinophil function in human eosinophilic and non-eosinophilic disorders.
Despite expanded availability of murine models (Table 1, Supplementary Table S2 Charcot-Leyden Crystal (CLC) protein/Galectin-10 39 for which intracellular and extracellular roles, for example, in granulogenesis during human eosinophil development, secretion of granule cationic proteins, and glycan-containing ligands, remain to be determined. Finally, no murine models exist that create "humanized" eosinophil mice as has been done, for example, with mast cells, 40 and current data from newly derived murine models (e.g., non-irradiated NBSGW mice engrafted with hematopoietic cells) have not been specifically evaluated for engraftment of eosinophils using available eosinophil cell surface markers. 41 None of the currently available models adequately replicate the various subtypes of HES or EGPA. 
Eosinophils in human disease
Delineating the basic biology of human eosinophils remains an impor- and their response to tissue components, such as matrix proteins, 48 fibroblasts, 49 epithelium, and other tissue-resident cells. 50 It is known that the engagement and expression of integrins can engage matrix proteins, such as fibronectin and laminin, and that these interactions alter eosinophil biology including degranulation and survival. 51, 52 Whether other changes in the tissue microenvironment (e.g., during morphogenesis, aging, wound development, and repair) influence the biology of resident and recruited eosinophils is less clear. Cell surface lectin receptors, such as Siglec-8, can engage specific glycan ligands on tissue and may selectively influence eosinophils. 53, 54 This bidirectional response and understanding of tissue microenvironments will be an important concept for future study in EADs.
Whereas a better understanding of basic eosinophil function is clearly a priority, well-designed translational studies are required for the application of basic science advances to human disease. These, in turn, depend on the development of clear diagnostic criteria, consistent nomenclature for standardization of acquisition, analyses, and histopathologic evaluation of biopsies and establishment of validated biomarkers of disease activity and treatment outcomes in clinical trials and daily practice. Although blood biomarkers tend to be favored for simplicity and ease of access, biomarkers based on other biological specimens, such as urine or nasal secretions, and organspecific biomarkers and scoring systems are also needed.
Eosinophil granule proteins
Eosinophils store a diverse array of cytokines and chemokines pre- 
Tissue eosinophils and eosinophil subtypes

Clinical and translational studies in EADs
Since the TREAD meeting, there has been a dramatic increase in the development and approval of novel therapies for treatment of both common and rare EADs. While this is exciting, some rare EADs remain understudied due to (1) difficulties in recruitment of rare patients and collecting of prospective samples during multicenter studies from which to perform mechanistic research, (2) adequately powered studies from which to draw evidence-based conclusions, and (3) logistical challenges that arise from attempts to create cohesive research plans with uniform collection of biological samples, data-coordination, and analysis. Investigators studying rare EADs would benefit from the creation of research networks and registries for collaboration and pooling of resources. In addition, a comprehensive guide to the resources ( Table 1 ) and organizations that provide funding (Table 3) to researchers in rare diseases, specifically in EADs, would help foster increased engagement of new investigators in this area. Recommendations for overcoming these challenges are summarized in the next section.
Registries
The 
Patient and clinician reported outcome measures
The development and validation of disease-specific quality of life 76 EoE-QOL-A (EoE Quality of Life-Adults), 77 and PEESS v2.0 (Pediatric Eosinophilic Esophagitis Symptom Severity)). 78 The lack of similar metrics in other EADs, including EGID involving the stomach, small bowel, and colon, are due, in large part, to the heterogeneity of symptoms when multiple organs are affected. The confounding effects of medication-related side effects can also hinder the 
Academia-industry collaborations
The importance of leveraging clinical trials to collect data to enhance understanding of underlying disease mechanisms in EADs was uniformly endorsed by the RE-TREAD participants. One example of this is the EGPA study mentioned above that was co-sponsored by the NIH and GlaxoSmithKline (GSK), and included extramural NIH-funding to support mechanistic studies at 5 US academic sites. 79 Standard operating procedures were implemented for tracking blood, sputum, and urine samples through a data coordinating center in order to collect blood samples for quantification of cytokines and other mediators for analysis of treatment response and evaluation of exacerbations, and to collect blood and tissue for transcriptome profiling for exploration of mechanisms of disease. During the conduct of the study, special attention was paid to operating procedures for internal governance and transparency requirements, especially in consideration of FDA submission of this pivotal phase 3 study. This collaboration serves as a model for future design of clinical studies in EADs with incorporation of a priori defined research goals, and pooling of resources, expertise, and rare-disease patients across multiple institutions.
Creation of more specific diagnostic codes for EADs
The United States applies a clinical modifier (ICD10-CM) to the Inter- Within a few months of the meeting, 11 EADs (Table 2) 
Biomarkers
Although peripheral absolute eosinophil counts (AEC) have tradition- [81] [82] [83] Whether this was due to lack of sufficient tissue depletion, irreversible structural changes in the esophagus, a lack of direct eosinophil contribution to disease pathogenesis, or other factors is unclear.
Markers of eosinophil activation, including eosinophil granule proteins levels in blood, tissue, and body fluids, may be more easily quantifiable markers of disease activity and have been used as biomarkers in some studies, including a multicenter, double-blind, placebo-controlled trial of mepolizumab in HES, 80 asthma, 84, 85 and EoE. 9 However, differences in the specific granule proteins measured, and methodologies used between studies, currently make it difficult to draw generalizable conclusions.
A major advancement since the TREAD meeting is the development of noninvasive techniques to assess eosinophil granule deposition. These include the use of body fluids, such as saliva, stool, and urine, as surrogates for tissue biopsies and the esophageal string test. 9 To capture a standardized metric of blood eosinophilia and activation states, a gene expression metric was derived for blood samples collected in PAXgene RNA tubes as part of a clinical trial of anti-IL-13 antibody in asthma. 37 This eosinophil-related gene signature metric is neither age dependent nor lab dependent and may capture activation states as well as proportions of eosinophils in a peripheral blood sample. The applicability of this metric to other EADs remains to be seen.
Several biomarkers have been developed to characterize type 2/eosinophilic inflammation in asthma, including fractional exhaled nitric oxide (FeNO), and serum or plasma periostin protein levels. 86 These biomarkers correlate with eosinophilic airway inflammation in asthma, but have not been explored more broadly in EADs. Additional examples of biomarkers with applicability restricted to a single or selected group of EADs include TARC/CCL17, 87 or quantification of the clonal population 88 in lymphoid HES, functional or structural markers of disease in EoE (e.g., EndoFLIP to measure esophageal distensibility), and tyrosine kinase mutations in myeloid HES. Further demonstration of the validity of these biomarkers is needed.
Expansion into new therapeutic areas in EADs
Since Unrelated to the IL-5 axis, a new small molecule agent, dexpramipexole (Knopp Biosciences), was noted to have coincidental eosinophil-lowering activity during its initial clinical development in amyotrophic lateral sclerosis. 93 In an open-label phase 2 study in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), dexpramipexole lowered blood eosinophils by 94% from baseline (P < 0.001) and polyp eosinophils by 97% (P = 0.001). 94 Promising results of a recently completed phase 2 trial in HES should be available soon. 95 Clinical trials of other agents that target eosinophils, including antibodies to Siglec-8, are planned or ongoing for non-EADs (NCT02734849; NCT02808793; NCT03379311) and are likely to provide additional insights into EADs in future planned trials.
Finally, a number of agents that target pathways important in eosinophilic inflammation, rather than eosinophils themselves, are being studied or have been approved for a variety of common disorders where eosinophils may play a role. These include anti-IL-13
(lebrikizumab, tralokinumab, RCP4046), anti-IL-4R (dupilumab), anti-TSLP (tezepelumab), 96 and anti-IL-31 (nemolizumab), various of which have demonstrated efficacy in eosinophilic asthma, 97 atopic dermatitis (NCT02525094 98,99 ), nasal polyposis, 100 and EoE (NCT02379052 101 ).
An important secondary benefit of clinical trials of targeted agents in these disorders is the mechanistic insights provided regarding the role of eosinophils in disease pathogenesis. For example, the efficacy of mepolizumab, reslizumab, and benralizumab in eosinophilic asthma confirmed a role for eosinophils in asthma exacerbations, but also helped to promote the concept of asthma endotypes. 102 In contrast, the demonstration that antibodies to IL-13 and IL-4R are also effective in reducing exacerbations and FeNO levels in eosinophilic asthma, despite a transient increase in circulating eosinophils, 34 highlights the differences between blood and tissue eosinophils and their roles in disease. As the numbers of targeting therapies continue to expand, it will become increasingly important to determine the EADs, and perhaps even subtypes of EADs, that are most likely to benefit from avail- 
New biological techniques applied to EADs
Major advances in biomedical technology, bioinformatics, and their application since 2012 have led to novel approaches to study EADs.
A significant reduction in the cost of genome sequencing and a corresponding ability to aggregate and analyze large datasets has made the application of these approaches to the "eosinophilome" possible. The potential of these developments to deliver precision and personalized care 103 in EADs cannot be overemphasized.
"Omics"
Notable advances include application of "omic" approaches, particularly proteomics and transcriptomics to human eosinophil
immunobiology. An in-depth assessment of the eosinophil proteome with demonstration of upregulation of phosphoproteins with IL-5 stimulation was described. 104 The proteome and phosphoproteome were also noted to change after stimulation, including responses to IL-5, IL-3, and GM-CSF. 105 Other studies show the value of applying transcriptomics to human eosinophil biology, with evolution from gene array studies to RNAseq methodology. Gene array analysis showed upregulated transcripts in bronchoalveolar lavage eosinophils after segmental allergen challenge, 106 and TGF-target genes in peripheral blood eosinophils were shown to be expressed by RNAseq. 107 Transcriptome analysis of esophageal tissue specimens was shown to be effective in making molecular diagnoses of EoE and differentiating EoE from reflux disease, 108 and glycomics analyses are being used to identify glycoproteins in mucins and other endogenous tissue structures capable of directly interacting with eosinophil lectin receptors 109 further paving the way for personalized approaches to diagnosis of EADs. Identified future challenges include mapping the interaction between the microbiome and eosinophil functional responses and characterization of eosinophil-specific and eosinophil subset-specific signatures in healthy and diseased tissues using single cell sequencing and other novel techniques.
The use of laser capture dissection and single cell sequencing, 110 multiplex florescence in-situ hybridization analysis, 111 and omics 112 have already proven useful in the study of new targets in murine models. Gene editing and clustered regularly interspaced short palindromic repeat (CRISPR) and CRISPR-associated (Cas) technology provide faster generation of floxed mice to genes of interest in eosinophils, and in cell lines CRISPR/Cas has been used to study the FIP1L1-PDGFRA fusion gene to further understand mechanisms in myeloid HES. 113 Conceivably, CRISPR may be used with humanized mice in the future as a tool to manipulate transferred human eosinophils.
Outstanding questions in the field of EADs include the lack of predictors for the development of EADs, as well as optimal treatments for tissue specific manifestations, such as in EGIDs. Using an omics approach, it is hopeful that phenotypic and genomic data, can be analyzed as a function of environment, epigenome, transcriptome, proteome, metabolome, glycome, and microbiome. Indeed, genomic data has already identified regions that confer susceptibility to eosinophilia. 114 The key transcriptional programs responsible for eosinophil development are emerging. 115 The eosinophil proteome has been preliminarily mapped out, 104 and eosinophils have been shown to regulate the intestinal microbiome. 18 De novo mutations and genome wide methylation patterns responsible for HES have been initiated. 116 The EoE transcriptome has been uncovered, providing new insight into disease pathogenesis and providing the framework for a diagnostic PCR-based diagnostic panel. 108, 117 Such an approach has facilitated new drug development such as anti-Type 2 cytokine therapy. 118 Future efforts in the area of technology, biomedical advances, 
DISCUSSION
The goals of both the prior TREAD meeting 1 and the most recent RE-TREAD meeting were to convene leading international experts in eosinophil biology and EADs to work together to help move the field toward improved understanding, diagnosis, and treatment of EADs. The topics considered ranged from basic eosinophil biology to clinical trials. While progress has been made during these past 5 years, significant gaps remain in our understanding of EAD initiation, development, evolution, progression, organ specificity, and remission.
With the unique exception of the highly effective and perhaps "curative" use of tyrosine kinase inhibitors for PDGFR-associated myeloid neoplasms, 119,120 treatment paradigms for HES remain mostly empiric. 121 Fortunately, the last 5 years have witnessed the sequential FDA approval of 3 new-in-class anti-eosinophil biologics that target IL-5 or its receptor. 122 Such drugs are not only a welcome addition to the arsenal of therapies for EADs but are highly targeted and specific pharmacologic tools for dissecting the contribution of eosinophils to disease, adding timeliness to RE-TREAD. A prime example is the successful use of mepolizumab to treat EGPA, 79 which provided some mechanistic insight into the question of whether eosinophils truly play a role in the pathogenesis of a complex multisystem vasculitic disorder. At a minimum, withdrawal of corticosteroids did not result in worsening of vasculitis as has occurred with various other steroidsparing medications used for asthma. 123 Although not yet approved for use in eosinophilic disorders other than asthma and EGPA, there is strong evidence that mepolizumab (and other biologics targeting the IL-5 axis) have clinically beneficial activity in HES, lymphoid HES, and perhaps EGID. 122, 124 Since their cost and the paucity of available data, including uncertainty on optimal dosing, are likely to make off-label use in these disorders difficult, the importance of well-designed clinical trials, especially in rare EAD, remains a priority. Moreover, as the number of approved targeted agents increases, direct comparisons between the different agents and the safety and efficacy of combination therapies will be essential to create optimized outcomes based recommendations to help guide physicians.
It is hoped that this RE-TREAD report will once again help to keep the field of basic eosinophil immunobiology and translational efforts aimed at EADs focused on common goals that will benefit patients. 
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